Ixaltis

France
Vaux-sur-Seine, Île-de-France, France

Company profile

Ixaltis company profile

Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé. The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders. IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Country code
FR
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Total equity funding
$8M
Last funding
Series Unknown / $8M / 2016-05-31
Last equity funding
Series Unknown / $8M
Investors
5
Founders
6
Articles
1

Founders and investors

Founders

Christian ChavyPascal RischmannPhilippe LluelRoberto GradnikStefano PaleaXavier Gamé

Investors

IRDIIXO Private EquityPierre Olivier GoineauPrincipia SGRSofimac Investment Managers